About the Speaker

John McCamant
Editor
Medical Technology Stock Letter
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Register Free
By submitting your email address you agree to receive emails on MoneyShow events, special offers, and updates.

Speaker Schedule
Thursday, January 26, 2023, 11:15 am - 11:45 am
Finding Best in Class Drugs Like MDGL
John McCamant |Medical Technology Stock Letter
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.

Reserve Your Free Pass Today!

Register Now